Skip to main content

Sound Advice: November 3, 2021

Medicare 201 

Coverage of outpatient prescription drugs under Medicare Part D began on January 1, 2006.  Part D is an optional plan that is available to everyone enrolled in Medicare Part A and Part B.  There are numerous plans available and there are considerable differences in ongoing plan prices as well as drug costs.

Let’s begin with some basics.  One of the most important is the formulary, the list of prescription drugs (both name brand and generic) preferred by the health plan.  There are copays for those that are on the list.  For drugs not on the list, the patient may have to pay full price.  Formularies change annually and drugs that have been included in the formulary may switch from preferred to nonpreferred or be removed entirely.

Within the formulary there are different tiers for the drugs included.  Tier 1 is generic drugs, which have the lowest possible copayment.  Tier 2 includes brand-name drugs that do not have a generic option.  Tier 3 consists of nonpreferred, brand-name drugs that do have a generic option. Tier 4 includes nonpreferred brand-name drugs and some nonpreferred, high-cost generic drugs.  With Part D coverage, the copayment costs can range from just a few dollars to fairly hefty sums. 

In addition, there are preferred pharmacies.  A preferred pharmacy network is a group of pharmacies willing to give the plans a larger discount than those offered by other pharmacies.

That leads us to the next issue: the stages of coverage.

Stage 1 of Part D is when you pay the full cost of prescriptions until you meet the annual deductible, which may be as little as zero or much higher, depending on the plan selected. 

Stage 2 of Part D is when the plan pays for a portion of the prescription drug you purchase, as long as the drug is covered under the plan’s formulary.  The copay is determined by the tier level assigned to the drug.  This stage ends when the amount spent by you and your plan adds up to the coverage limit set by Medicare for that year.  The limit for 2022 is $4,430.

Stage 3 of Part D is known as the coverage gap (a.k.a., the donut hole) for those whose spending on prescription drugs has exceeded the Stage 2 limit.  When in Stage 3, participants will pay 25% of the plan’s cost for covered brand-name and generic drugs.  Stage 3 ends when the total spending for covered drugs reaches $7,050.  This number is the total of copays, yearly deductible, and what has been paid for drugs in the coverage gap.

Stage 4 of Part D is known as catastrophic coverage.  In this stage, the plan and the government pay for about 95% of the cost.  Participants in Stage 4 remain in this stage until the end of the coverage year. 

For more details, go to medicare.gov.

N. Russell Wayne, CFP®

Sound Asset Management Inc.

Weston, CT  06883

203-222-9370

www.soundasset.com

www.soundasset.blogspot.com

Any questions?  Please contact me at nrwayne@soundasset.com

Comments

Popular posts from this blog

Sound Advice: January 3, 2025

2025 Market Forecasts: Stupidity Taken To An Extreme   If you know anything about stock market performance, you can only gag at the nonsense “esteemed forecasters” are now putting forth about the prospective path of stocks in the year ahead.   Our cousins in the UK would call this rubbish.   I would not be as kind. Leading the Ship of Fools is the forecast from the Chief Investment Strategist at Oppenheimer who is looking for a year-end 2025 level for the Standard & Poor’s Index of 7,100, a whopping 21% increase from the most recent standing.   Indeed, most of these folks are looking for double-digit gains.   Only two expect stocks to weaken. In the last 30 years, the market has risen by more than 20% only 15 times.   The exceptional span during that time was 1996-1999, which accounted for four of those jumps.   What followed in 2000 through 2002 was the polar opposite: 2000:      -9.1% 2001:     -11.9% ...

Sound Advice: January 15, 2025

Why investors shouldn't pay attention to Wall Street forecasts   Investors shouldn't pay attention to Wall Street forecasts for several compelling reasons: Poor accuracy Wall Street forecasts have a terrible track record of accuracy. Studies show that their predictions are often no better than random chance, with accuracy rates as low as 47%   Some prominent analysts even perform worse, with accuracy ratings as low as 35% Consistent overestimation Analysts consistently overestimate earnings growth, predicting 10-12%                 annual growth when the reality is closer to 6%.   This overoptimism can                 lead investors to make overly aggressive bets in the market. Inability to predict unpredictable events The stock market is influenced by numerous unpredictable factors, including geopolitical events, technological changes, and company-specific news.   Anal...

Sound Advice: October 12, 2022

More Pain Ahead? It’s been a difficult year for the investment markets, but tough times have happened before and they will certainly happen again.   Sometimes recoveries are relatively quick and sometimes a hefty dose of patience is required.   No two downdrafts are alike, but the net result is always a rebound to even higher levels than seen before. One of the most uncomfortable stretches over the last half century took place during the oil embargo days of the early and mid-1970s.   Market valuations fell to the high single digits, a level that was about half the historic average.   For investors, this was one of the great sales of all time.   Those who had the courage to get aboard reaped huge rewards. More recent pullbacks of note took place during the dot.com days of the turn of the millennium and the banking crisis of 2008-9.   The former period was marked by what appeared to be investors’ absolute indifference to longstanding measures of reasona...